The phosphoinositide 3-kinase (PI3K) pathway is a ... through loss of the PTEN tumour suppressor. Inhibitors that target key components of this pathway, including PI3K, AKT and mammalian target ...

通过共转染 miR-374-5p 模拟物和 PI3K/AKT 通路抑制剂 LY294002 进行拯救实验，发现抑制剂能够逆转 miR-374-5p 对成骨细胞分化的抑制作用。这揭示了 miR-374-5p 通过激活 PTEN/PI3K/AKT 通路抑制成骨细胞分化的潜在机制56。 综合研究结论和讨论部分，此次研究首次揭示了 miR-374 ...

Mutations in PIK3CA, AKT1, and alterations in PTEN occur frequently ... of Truqap “reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need ...

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...

or the loss of a tumor-suppressing protein called PTEN. "Up to 25–40% of BC cases exhibit variations that hyperactivate the PI3K/Akt/mTOR pathway, underscoring its critical role in oncogenesis." ...

and PTEN-mutated breast cancer. So far, no AKT inhibitors have been brought to market, but several remain in clinical development. Roche's decision to drop the programme comes after AstraZeneca's ...

The biomarker analysis found patients with certain mutations in the PI3K/AKT/mTOR pathway and MAPK pathway may be resistant to Truqap.

A new study on the genetic causes of the PTEN Hamartoma Tumour Syndrome (PHTS) has found that inhibitors of the PI3ka pathway, commonly used as anticancer drugs, are also effective against this ...